Loading
A phase 3 trial of Rezvilutamide run by Jiangsu HengRui Medicine Co., Ltd. in prostate cancer, now recruiting.
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT07241416 by Jiangsu HengRui Medicine Co., Ltd., with 206 participants planned, started 2025-12-05. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs).
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs).
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/